WO2008126797A1 - 微粉砕化有機化合物粒子の製造方法 - Google Patents
微粉砕化有機化合物粒子の製造方法 Download PDFInfo
- Publication number
- WO2008126797A1 WO2008126797A1 PCT/JP2008/056799 JP2008056799W WO2008126797A1 WO 2008126797 A1 WO2008126797 A1 WO 2008126797A1 JP 2008056799 W JP2008056799 W JP 2008056799W WO 2008126797 A1 WO2008126797 A1 WO 2008126797A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- organic compound
- compound particle
- poorly water
- producing
- medical use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008800084620A CN101636150B (zh) | 2007-04-06 | 2008-04-04 | 难水溶性医疗用有机化合物微粒子的制造方法 |
EP08739905.1A EP2143423B1 (en) | 2007-04-06 | 2008-04-04 | Method for producing pulverized organic compound particle |
KR1020097014759A KR101369061B1 (ko) | 2007-04-06 | 2008-04-04 | 미분쇄화 유기 화합물 입자의 제조 방법 |
ES08739905.1T ES2563979T3 (es) | 2007-04-06 | 2008-04-04 | Método para producción de partículas de compuesto orgánico pulverizadas |
JP2009509328A JP5317960B2 (ja) | 2007-04-06 | 2008-04-04 | 微粉砕化有機化合物粒子の製造方法 |
CA2679929A CA2679929C (en) | 2007-04-06 | 2008-04-04 | Method for producing finely pulverized organic compound particle |
IL201169A IL201169A (en) | 2007-04-06 | 2009-09-24 | A method for producing crushed particles of organic compound |
US12/585,786 US8226983B2 (en) | 2007-04-06 | 2009-09-24 | Method for producing pulverized organic compound particle |
US13/484,460 US20120237768A1 (en) | 2007-04-06 | 2012-05-31 | Method for producing pulverized organic compound particle |
IL223087A IL223087A (en) | 2007-04-06 | 2012-11-18 | Thin crushed organic compound particles |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-100902 | 2007-04-06 | ||
JP2007100902 | 2007-04-06 | ||
JP2007-210370 | 2007-08-10 | ||
JP2007210370 | 2007-08-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/585,786 Continuation US8226983B2 (en) | 2007-04-06 | 2009-09-24 | Method for producing pulverized organic compound particle |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008126797A1 true WO2008126797A1 (ja) | 2008-10-23 |
Family
ID=39863895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/056799 WO2008126797A1 (ja) | 2007-04-06 | 2008-04-04 | 微粉砕化有機化合物粒子の製造方法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8226983B2 (ja) |
EP (2) | EP2679219A1 (ja) |
JP (1) | JP5317960B2 (ja) |
KR (1) | KR101369061B1 (ja) |
CN (1) | CN101636150B (ja) |
CA (1) | CA2679929C (ja) |
ES (1) | ES2563979T3 (ja) |
HU (1) | HUE028529T2 (ja) |
IL (2) | IL201169A (ja) |
TW (1) | TWI405590B (ja) |
WO (1) | WO2008126797A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010052896A1 (ja) * | 2008-11-04 | 2010-05-14 | 日揮株式会社 | プロピオン酸フルチカゾンを含む局所投与剤 |
WO2011001214A1 (en) * | 2009-06-30 | 2011-01-06 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Surface amorphization of phenprobamate |
WO2011118960A2 (ko) | 2010-03-22 | 2011-09-29 | (주)바이오시네틱스 | 나노입자 제조방법 |
WO2013042978A1 (ko) | 2011-09-21 | 2013-03-28 | (주)바이오시네틱스 | 나노입자 제조방법 |
JP2013525337A (ja) * | 2010-04-20 | 2013-06-20 | シプラ・リミテッド | 医薬組成物 |
WO2013168437A1 (ja) | 2012-05-11 | 2013-11-14 | 株式会社アクティバスファーマ | 有機化合物ナノ粉体、その製造方法ならびに懸濁液 |
JP5536654B2 (ja) * | 2008-09-19 | 2014-07-02 | 株式会社アクティバスファーマ | 医療用複合有機化合物粉体、その製造方法ならびに懸濁液 |
JP2014518284A (ja) * | 2011-07-07 | 2014-07-28 | アーキュール,インコーポレイティド | ピロロキノリニル−ピロリジン−2,5−ジオン製剤及びその調製方法及び使用方法 |
WO2016181935A1 (ja) * | 2015-05-08 | 2016-11-17 | 株式会社アクティバスファーマ | グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤 |
JP2018516907A (ja) * | 2015-06-04 | 2018-06-28 | クリティテック・インコーポレイテッド | タキサン粒子およびその使用 |
JP2019502697A (ja) * | 2015-12-15 | 2019-01-31 | ホビオネ サイエンティア リミテッド | 呼吸域ザフィルルカスト粒子の調製方法 |
RU2694221C1 (ru) * | 2018-12-14 | 2019-07-10 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Противовоспалительный препарат на основе кетопрофена и способ его получения |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI1014275B8 (pt) | 2009-04-24 | 2021-05-25 | Iceutica Pty Ltd | composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos |
CA2786618C (en) * | 2010-01-15 | 2016-04-12 | Lithera, Inc. | Lyophilized cake formulations |
CA2814445A1 (en) | 2010-10-12 | 2012-04-19 | Cipla Limited | Pharmaceutical composition |
JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
WO2013049621A1 (en) * | 2011-09-29 | 2013-04-04 | The Board Of Regents Of The University Of Oklahoma | Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof |
PT106237B (pt) | 2012-03-30 | 2015-03-19 | Hovione Farmaci Ncia S A | Produção de partículas substancialmente monodispersas utilizando moagem e separação por membranas |
CN103588846B (zh) * | 2012-08-15 | 2016-08-03 | 重庆华邦制药有限公司 | 一种丙酸氟替卡松微粒的制备方法及其用途 |
TWI691341B (zh) * | 2013-11-08 | 2020-04-21 | 日商活效製藥股份有限公司 | 含有巨環內酯系抗菌劑之奈米微粒子之水性懸濁液劑 |
US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
JP2016119898A (ja) * | 2014-12-16 | 2016-07-07 | ライコード・リミテツド | 着色剤特性が改善されたリコピン組成物 |
CN114588270A (zh) | 2015-09-16 | 2022-06-07 | Dfb索里亚有限责任公司 | 包含紫杉烷类纳米颗粒的组合物及其用途 |
DK3439635T3 (da) | 2016-04-04 | 2021-03-08 | Crititech Inc | Formuleringer til behandling af fast tumor |
CN108807919B (zh) * | 2016-09-23 | 2021-01-19 | 河北工业大学 | 一种三维碳架的制备方法 |
WO2018170196A1 (en) | 2017-03-15 | 2018-09-20 | Dfb Soria, Llc | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes |
SG11201909840TA (en) | 2017-06-09 | 2019-11-28 | Crititech Inc | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
BR112019022720A2 (pt) | 2017-06-14 | 2020-05-12 | Crititech, Inc. | Métodos para tratar distúrbios pulmonares |
CN111278436A (zh) | 2017-10-03 | 2020-06-12 | 克里蒂泰克公司 | 局部递送抗肿瘤颗粒与全身递送免疫治疗剂相结合用于治疗癌症 |
EP3765035A4 (en) | 2018-03-16 | 2021-10-27 | DFB Soria, LLC | TOPICAL THERAPY FOR TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND ETERNAL CANCER USING TAXANNANO PARTICLES |
CN109232389B (zh) * | 2018-05-15 | 2021-10-08 | 迪嘉药业集团有限公司 | 一种小粒度硝苯地平的结晶制备方法 |
CN113081993A (zh) * | 2021-04-15 | 2021-07-09 | 海南通用三洋药业有限公司 | 一种尼麦角林片剂的制备方法 |
CN113582913B (zh) * | 2021-08-18 | 2023-01-03 | 河北广祥制药有限公司 | 一种连续精制硝苯地平的方法 |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5817167A (ja) | 1981-07-06 | 1983-02-01 | モベイ・コ−ポレ−ション | 顔料のコンデイシヨニング方法 |
JPH0366613A (ja) * | 1989-08-04 | 1991-03-22 | Tanabe Seiyaku Co Ltd | 難溶性薬物の超微粒子化法 |
JPH03131355A (ja) * | 1989-10-17 | 1991-06-04 | Sankyo Co Ltd | 難溶性化合物の湿式粉砕方法 |
JPH04295420A (ja) * | 1991-01-25 | 1992-10-20 | Sterling Winthrop Inc | 表面変性薬物微小粒子 |
JPH06228454A (ja) * | 1991-03-07 | 1994-08-16 | Toyo Ink Mfg Co Ltd | β型ジオキサジン顔料の製造法 |
US5626662A (en) | 1994-04-21 | 1997-05-06 | Hoechst Aktiengesellschaft | Fine division in the preparation of organic pigments |
JPH10330799A (ja) * | 1997-06-04 | 1998-12-15 | Lion Corp | 泡状殺菌洗浄剤組成物 |
JPH11100317A (ja) | 1997-07-26 | 1999-04-13 | Ciba Specialty Chem Holding Inc | Uv−防御剤組成物 |
US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
JP2002511398A (ja) | 1998-04-09 | 2002-04-16 | エフ.ホフマン−ラ ロシュ アーゲー | 圧縮ガス及び界面活性剤に溶解することによって(サブ)ミクロンレベルの大きさの粒子を製造する方法 |
JP2002518318A (ja) | 1998-06-19 | 2002-06-25 | アールティーピー・ファーマ・インコーポレーテッド | 水に溶けない化合物のサブミクロン粒子を生成させる方法 |
JP2003286105A (ja) | 2002-03-27 | 2003-10-07 | Kumiai Chem Ind Co Ltd | 顆粒状水和剤 |
JP2003342493A (ja) * | 2002-05-27 | 2003-12-03 | Konica Minolta Holdings Inc | 有機化合物の精製方法 |
JP2004330078A (ja) | 2003-05-07 | 2004-11-25 | Morinaga Milk Ind Co Ltd | 食品の微粉砕方法および飲食物 |
JP2005008806A (ja) * | 2003-06-20 | 2005-01-13 | Toyo Ink Mfg Co Ltd | β型銅フタロシアニン顔料の製造方法 |
JP2006089386A (ja) | 2004-09-21 | 2006-04-06 | Nippon Tenganyaku Kenkyusho:Kk | ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物 |
JP2006182992A (ja) | 2004-12-28 | 2006-07-13 | Usm Kenkyusho:Kk | 絹微粒子溶液及び絹微粒子粉末の製造方法並びに絹微粒子を含む材料 |
WO2006087919A1 (ja) * | 2005-01-28 | 2006-08-24 | Takeda Pharmaceutical Company Limited | 難水溶性物質含有微細化組成物 |
JP2006255519A (ja) * | 2005-03-15 | 2006-09-28 | Masumi Kusunoki | 媒体循環型粉砕装置 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
CN1211164C (zh) * | 2000-05-10 | 2005-07-20 | 斯凯伊药品加拿大公司 | 介质研磨 |
JP4969761B2 (ja) * | 2000-08-31 | 2012-07-04 | オバン・エナジー・リミテッド | 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法 |
EP1503737B1 (en) * | 2002-05-06 | 2009-01-07 | Elan Pharma International Limited | Nanoparticulate nystatin formulations |
AU2003261167A1 (en) * | 2002-07-16 | 2004-02-02 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
JP5080445B2 (ja) * | 2005-04-13 | 2012-11-21 | アボット ゲーエムベーハー ウント コー. カーゲー | 超微粒子懸濁液及び超微粒子を穏やかに製造する方法並びにその使用 |
EP1973527B1 (en) * | 2005-12-15 | 2009-10-07 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for parenteral administration |
-
2008
- 2008-04-03 TW TW097112153A patent/TWI405590B/zh active
- 2008-04-04 HU HUE08739905A patent/HUE028529T2/en unknown
- 2008-04-04 KR KR1020097014759A patent/KR101369061B1/ko active IP Right Grant
- 2008-04-04 WO PCT/JP2008/056799 patent/WO2008126797A1/ja active Application Filing
- 2008-04-04 EP EP13003854.0A patent/EP2679219A1/en not_active Withdrawn
- 2008-04-04 CA CA2679929A patent/CA2679929C/en active Active
- 2008-04-04 CN CN2008800084620A patent/CN101636150B/zh active Active
- 2008-04-04 ES ES08739905.1T patent/ES2563979T3/es active Active
- 2008-04-04 EP EP08739905.1A patent/EP2143423B1/en active Active
- 2008-04-04 JP JP2009509328A patent/JP5317960B2/ja active Active
-
2009
- 2009-09-24 US US12/585,786 patent/US8226983B2/en active Active
- 2009-09-24 IL IL201169A patent/IL201169A/en active IP Right Grant
-
2012
- 2012-05-31 US US13/484,460 patent/US20120237768A1/en not_active Abandoned
- 2012-11-18 IL IL223087A patent/IL223087A/en active IP Right Grant
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5817167A (ja) | 1981-07-06 | 1983-02-01 | モベイ・コ−ポレ−ション | 顔料のコンデイシヨニング方法 |
JPH0366613A (ja) * | 1989-08-04 | 1991-03-22 | Tanabe Seiyaku Co Ltd | 難溶性薬物の超微粒子化法 |
JP2642486B2 (ja) | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
JPH03131355A (ja) * | 1989-10-17 | 1991-06-04 | Sankyo Co Ltd | 難溶性化合物の湿式粉砕方法 |
JP3602546B2 (ja) | 1991-01-25 | 2004-12-15 | エラン ファーマ インターナショナル,リミティド | 表面変性薬物微小粒子 |
JPH04295420A (ja) * | 1991-01-25 | 1992-10-20 | Sterling Winthrop Inc | 表面変性薬物微小粒子 |
JPH06228454A (ja) * | 1991-03-07 | 1994-08-16 | Toyo Ink Mfg Co Ltd | β型ジオキサジン顔料の製造法 |
JP2683458B2 (ja) | 1991-03-07 | 1997-11-26 | 東洋インキ製造株式会社 | β型ジオキサジン顔料の製造法 |
US5626662A (en) | 1994-04-21 | 1997-05-06 | Hoechst Aktiengesellschaft | Fine division in the preparation of organic pigments |
JPH10330799A (ja) * | 1997-06-04 | 1998-12-15 | Lion Corp | 泡状殺菌洗浄剤組成物 |
JPH11100317A (ja) | 1997-07-26 | 1999-04-13 | Ciba Specialty Chem Holding Inc | Uv−防御剤組成物 |
JP2002511398A (ja) | 1998-04-09 | 2002-04-16 | エフ.ホフマン−ラ ロシュ アーゲー | 圧縮ガス及び界面活性剤に溶解することによって(サブ)ミクロンレベルの大きさの粒子を製造する方法 |
US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
JP2002518318A (ja) | 1998-06-19 | 2002-06-25 | アールティーピー・ファーマ・インコーポレーテッド | 水に溶けない化合物のサブミクロン粒子を生成させる方法 |
JP2003286105A (ja) | 2002-03-27 | 2003-10-07 | Kumiai Chem Ind Co Ltd | 顆粒状水和剤 |
JP2003342493A (ja) * | 2002-05-27 | 2003-12-03 | Konica Minolta Holdings Inc | 有機化合物の精製方法 |
JP2004330078A (ja) | 2003-05-07 | 2004-11-25 | Morinaga Milk Ind Co Ltd | 食品の微粉砕方法および飲食物 |
JP2005008806A (ja) * | 2003-06-20 | 2005-01-13 | Toyo Ink Mfg Co Ltd | β型銅フタロシアニン顔料の製造方法 |
JP2006089386A (ja) | 2004-09-21 | 2006-04-06 | Nippon Tenganyaku Kenkyusho:Kk | ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物 |
JP2006182992A (ja) | 2004-12-28 | 2006-07-13 | Usm Kenkyusho:Kk | 絹微粒子溶液及び絹微粒子粉末の製造方法並びに絹微粒子を含む材料 |
WO2006087919A1 (ja) * | 2005-01-28 | 2006-08-24 | Takeda Pharmaceutical Company Limited | 難水溶性物質含有微細化組成物 |
JP2006255519A (ja) * | 2005-03-15 | 2006-09-28 | Masumi Kusunoki | 媒体循環型粉砕装置 |
Non-Patent Citations (4)
Title |
---|
"Apparatus 3 for Dry Powder Inhalers", USP30-NF25, vol. 1, pages 220 - 240 |
KUWAHARA YOSHITAKA: "Pulverization Process in Fine Pulverization Region and Contamination", CUTTING-EDGE PULVERIZATION TECHNOLOGIES AND APPLICATIONS, 2005, pages 81 - 88 |
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 9, no. 1, 2004, pages 1 - 13 |
See also references of EP2143423A4 |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5536654B2 (ja) * | 2008-09-19 | 2014-07-02 | 株式会社アクティバスファーマ | 医療用複合有機化合物粉体、その製造方法ならびに懸濁液 |
WO2010052896A1 (ja) * | 2008-11-04 | 2010-05-14 | 日揮株式会社 | プロピオン酸フルチカゾンを含む局所投与剤 |
WO2011001214A1 (en) * | 2009-06-30 | 2011-01-06 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Surface amorphization of phenprobamate |
WO2011118960A2 (ko) | 2010-03-22 | 2011-09-29 | (주)바이오시네틱스 | 나노입자 제조방법 |
US8828445B2 (en) | 2010-03-22 | 2014-09-09 | Bio-Synectics Inc. | Method for preparing nano-particles utilizing a saccharide anti-coagulant |
JP2013525337A (ja) * | 2010-04-20 | 2013-06-20 | シプラ・リミテッド | 医薬組成物 |
JP2014518284A (ja) * | 2011-07-07 | 2014-07-28 | アーキュール,インコーポレイティド | ピロロキノリニル−ピロリジン−2,5−ジオン製剤及びその調製方法及び使用方法 |
US9439871B2 (en) | 2011-09-21 | 2016-09-13 | Bio-Synectics, Inc. | Method for preparing nano particles |
WO2013042978A1 (ko) | 2011-09-21 | 2013-03-28 | (주)바이오시네틱스 | 나노입자 제조방법 |
TWI579004B (zh) * | 2012-05-11 | 2017-04-21 | 活效製藥股份有限公司 | 有機化合物奈米粉末、其製造方法及懸浮液 |
CN104203217A (zh) * | 2012-05-11 | 2014-12-10 | 株式会社活效制药 | 有机化合物纳米粉体及其制造方法、以及悬浮液 |
JPWO2013168437A1 (ja) * | 2012-05-11 | 2016-01-07 | 株式会社アクティバスファーマ | 有機化合物ナノ粉体、その製造方法ならびに懸濁液 |
US9278071B2 (en) | 2012-05-11 | 2016-03-08 | Activus Pharma Co., Ltd. | Organic compound nano-powder, method for producing the same and suspension |
WO2013168437A1 (ja) | 2012-05-11 | 2013-11-14 | 株式会社アクティバスファーマ | 有機化合物ナノ粉体、その製造方法ならびに懸濁液 |
RU2613109C2 (ru) * | 2012-05-11 | 2017-03-15 | Активус Фарма Ко., Лтд. | Нанопорошки органических соединений, способы их получения и их суспензии |
JPWO2016181935A1 (ja) * | 2015-05-08 | 2018-02-22 | 株式会社アクティバスファーマ | グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤 |
WO2016181935A1 (ja) * | 2015-05-08 | 2016-11-17 | 株式会社アクティバスファーマ | グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤 |
US10588913B2 (en) | 2015-05-08 | 2020-03-17 | Activus Pharma Co., Ltd. | Aqueous suspension agent containing glucocorticosteroid nanoparticles |
US11376262B2 (en) | 2015-05-08 | 2022-07-05 | Activus Pharma Co., Ltd. | Method of treating an inflammatory or infectious disease |
IL255452B (en) * | 2015-05-08 | 2022-08-01 | Activus Pharma Co Ltd | Aqueous suspension containing glucocorticosteroid nanoparticles |
JP2018516907A (ja) * | 2015-06-04 | 2018-06-28 | クリティテック・インコーポレイテッド | タキサン粒子およびその使用 |
JP2022121532A (ja) * | 2015-06-04 | 2022-08-19 | クリティテック・インコーポレイテッド | タキサン粒子およびその使用 |
JP2019502697A (ja) * | 2015-12-15 | 2019-01-31 | ホビオネ サイエンティア リミテッド | 呼吸域ザフィルルカスト粒子の調製方法 |
US10987305B2 (en) | 2015-12-15 | 2021-04-27 | Cipla Limited | Preparation of respirable zafirlukast particles |
RU2694221C1 (ru) * | 2018-12-14 | 2019-07-10 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Противовоспалительный препарат на основе кетопрофена и способ его получения |
Also Published As
Publication number | Publication date |
---|---|
CA2679929A1 (en) | 2008-10-23 |
US20100016597A1 (en) | 2010-01-21 |
TWI405590B (zh) | 2013-08-21 |
IL201169A0 (en) | 2010-05-17 |
EP2679219A1 (en) | 2014-01-01 |
EP2143423B1 (en) | 2015-12-09 |
EP2143423A4 (en) | 2010-05-26 |
IL223087A (en) | 2014-06-30 |
US8226983B2 (en) | 2012-07-24 |
TW200906450A (en) | 2009-02-16 |
EP2143423A1 (en) | 2010-01-13 |
IL223087A0 (en) | 2012-12-31 |
CN101636150A (zh) | 2010-01-27 |
ES2563979T3 (es) | 2016-03-17 |
CN101636150B (zh) | 2013-12-04 |
CA2679929C (en) | 2014-12-16 |
JPWO2008126797A1 (ja) | 2010-07-22 |
KR20100014315A (ko) | 2010-02-10 |
KR101369061B1 (ko) | 2014-02-28 |
US20120237768A1 (en) | 2012-09-20 |
IL201169A (en) | 2013-08-29 |
HUE028529T2 (en) | 2016-12-28 |
JP5317960B2 (ja) | 2013-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008126797A1 (ja) | 微粉砕化有機化合物粒子の製造方法 | |
NZ614995A (en) | Methods for the preparation of biologically active compounds in nanoparticulate form | |
WO2007082299A3 (en) | Nanoparticle compositions and methods for making and using the same | |
WO2008051349A3 (en) | Improved ethanol product i on in fermentation of mixed sugars containing xylose in the presence of sugar alcohols | |
WO2009081386A3 (en) | A process for preparing nanoparticles | |
WO2013034421A3 (en) | Tooth remineralizing dentifrice | |
GB2482032B (en) | Coffee products and related processes | |
WO2011003034A3 (en) | Biological methods for preparing adipic acid | |
MX2012003373A (es) | Metodos para preparar particulas tipo virus derivadas de plantas. | |
WO2011022175A3 (en) | Compositions with improved dirt pickup resistance comprising layered double hydroxide particles | |
WO2009074679A3 (en) | Improved coated fertilizer | |
EP2345426A4 (en) | ORGANIC PULVRENT COMPOUND FOR MEDICAL USE, MANUFACTURING METHOD AND SUSPENSION THEREFROM | |
WO2011080336A3 (de) | Graphithaltiger formkörper und verfahren zu seiner herstellung | |
EP1852498A4 (en) | METHOD FOR PRODUCING A MILKY ACID BACTERIUM WITH ANTIALLERGENIC EFFECT | |
TN2011000536A1 (en) | A novel formulation of naproxen | |
GEP20115343B (en) | New method for preparing functionalised benzocyclo-butenes and its application to the synthesis of ivabradine and its addition salts with a pharmaceutically acceptable acid | |
WO2009010263A3 (de) | Prozess zur herstellung von bariumsulfat | |
WO2010040109A3 (en) | Methods for preparation of nanocrystals using a weak electron transfer agent and mismatched shell precursors | |
MY149137A (en) | Method for controlling the shape of talc particles | |
WO2011062420A3 (en) | Nanoparticles for tumor-targeting and processes for the preparation thereof | |
WO2011061516A3 (en) | Topical foam composition | |
WO2009080006A3 (de) | Neuer mariendistelextrakt, verfahren zur herstellung und verwendung | |
EP2116297A4 (en) | METHOD FOR THE PRODUCTION OF VESICLES, VESICLES OBTAINED BY THE METHOD, AND METHOD FOR THE PRODUCTION OF FROZEN PARTICLES FOR USE IN VESICLE MANUFACTURE | |
TW200740697A (en) | Yttrium oxide composition, method of preparing the same, and method of forming yttrium oxide layer using the same | |
WO2009063891A1 (ja) | 六方晶リン酸ジルコニウム粉末の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880008462.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08739905 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097014759 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2679929 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009509328 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201169 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008739905 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 223087 Country of ref document: IL |